Recently, Frontier Biotechnologies (hereinafter referred to as the company, stock code: 688221. SH) received the "Pharmaceutical Clinical Trial Approval Notice" issued by the National Medical Products Administration. The study of FB2001 nebulization inhalation will enroll patients with mild and moderate novel coronavirus (SARS-CoV-2) infection and people who need post-exposure prophylaxis. This authorization marks a significant milestone for Frontier and reinforces our ambition to provide treatment and prevention for COVID-19 pandemic.

FB2001 (generic name: Bofutrelvir), is a SARS-CoV-2 3CL protease inhibitor jointly developed by Frontier Biotechnologies, Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Wuhan Institute of Virology, Chinese Academy of Sciences. Frontier Biotech has exclusive global licenses to develop and commercialize FB2001 worldwide.